Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 82 entries
Sorted by: Best Match Show Resources per page
Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat.

Reviews in urology

Albala DM, Riebman JB, Kocharian R, Ilie B, Albanese J, Shen J, Ovington L, Batiller J.
PMID: 26028998
Rev Urol. 2015;17(1):25-30.

In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide...

Cite
Albala DM, Riebman JB, Kocharian R, et al. Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat. Rev Urol. 2015;17(1):25-30
Albala, D. M., Riebman, J. B., Kocharian, R., Ilie, B., Albanese, J., Shen, J., Ovington, L., & Batiller, J. (2015). Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat. Reviews in urology, 17(1), 25-30.
Albala, David M, et al. "Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat." Reviews in urology vol. 17,1 (2015): 25-30.
Albala DM, Riebman JB, Kocharian R, Ilie B, Albanese J, Shen J, Ovington L, Batiller J. Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat. Rev Urol. 2015;17(1):25-30. PMID: 26028998; PMCID: PMC4444771.
Copy Download .nbib Format: NLM
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

The oncologist

Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F.
PMID: 27317735
Oncologist. 2016 Jun;21(6):778. doi: 10.1634/theoncologist.2015-0312erratum.

No abstract available.

Cite
Alba E, Lluch A, Ribelles N, et al. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist. 2016;21(6):778doi: 10.1634/theoncologist.2015-0312erratum.
Alba, E., Lluch, A., Ribelles, N., Anton-Torres, A., Sanchez-Rovira, P., Albanell, J., Calvo, L., García-Asenjo, J. A., Palacios, J., Chacon, J. I., Ruiz, A., De la Haba-Rodriguez, J., Segui-Palmer, M. A., Cirauqui, B., Margeli, M., Plazaola, A., Barnadas, A., Casas, M., Caballero, R., Carrasco, E., & Rojo, F. (2016). High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. The oncologist, 21(6), 778. https://doi.org/10.1634/theoncologist.2015-0312erratum
Alba, Emilio, et al. "High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer." The oncologist vol. 21,6 (2016): 778. doi: https://doi.org/10.1634/theoncologist.2015-0312erratum
Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist. 2016 Jun;21(6):778. doi: 10.1634/theoncologist.2015-0312erratum. PMID: 27317735; PMCID: PMC4912359.
Copy Download .nbib Format: NLM
Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.

Drugs of today (Barcelona, Spain : 1998)

Albanell J, Baselga J.
PMID: 12973420
Drugs Today (Barc). 1999 Dec;35(12):931-46.

The HER2/neu gene encodes a 185 kDa transmembrane receptor (HER2) that belongs to the epidermal growth factor receptor family and has intrinsic tyrosine kinase activity. HER2 is overexpressed in 25-30% of breast cancers and is suggested to have a...

Cite
Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999;35(12):931-46
Albanell, J., & Baselga, J. (1999). Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs of today (Barcelona, Spain : 1998), 35(12), 931-46.
Albanell, J, and Baselga, J. "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer." Drugs of today (Barcelona, Spain : 1998) vol. 35,12 (1999): 931-46.
Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999 Dec;35(12):931-46. PMID: 12973420.
Copy Download .nbib Format: NLM
Diaqua-bis-(5-methyl-pyrazine-2-carboxyl-ato-κN,O)cadmium.

Acta crystallographica. Section E, Structure reports online

Albanez J, Brito I, Cárdenas A, López-Rodríguez M.
PMID: 22065674
Acta Crystallogr Sect E Struct Rep Online. 2011 Oct 01;67:m1339-40. doi: 10.1107/S1600536811035045. Epub 2011 Sep 14.

In the title compound, [Cd(C(6)H(5)N(2)O(2))(2)(H(2)O)(2)], the Cd(II) ion is coordinated in a severely distorted octa-hedral geometry. The N atoms are cis to each other, while the water O atoms and ligand O atoms are mutually trans. The crystal structure...

Cite
Albanez J, Brito I, Cárdenas A, et al. Diaqua-bis-(5-methyl-pyrazine-2-carboxyl-ato-κN,O)cadmium. Acta Crystallogr Sect E Struct Rep Online. 2011;67:m1339-40doi: 10.1107/S1600536811035045.
Albanez, J., Brito, I., Cárdenas, A., & López-Rodríguez, M. (2011). Diaqua-bis-(5-methyl-pyrazine-2-carboxyl-ato-κN,O)cadmium. Acta crystallographica. Section E, Structure reports online, 67m1339-40. https://doi.org/10.1107/S1600536811035045
Albanez, Joselyn, et al. "Diaqua-bis-(5-methyl-pyrazine-2-carboxyl-ato-κN,O)cadmium." Acta crystallographica. Section E, Structure reports online vol. 67 (2011): m1339-40. doi: https://doi.org/10.1107/S1600536811035045
Albanez J, Brito I, Cárdenas A, López-Rodríguez M. Diaqua-bis-(5-methyl-pyrazine-2-carboxyl-ato-κN,O)cadmium. Acta Crystallogr Sect E Struct Rep Online. 2011 Oct 01;67:m1339-40. doi: 10.1107/S1600536811035045. Epub 2011 Sep 14. PMID: 22065674; PMCID: PMC3201227.
Copy Download .nbib Format: NLM
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Frontiers in immunology

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.
PMID: 29181007
Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017.

Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy significantly improves relapse-free and overall survival in patients with early-stage...

Cite
Muntasell A, Cabo M, Servitja S, et al. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017;8:1544doi: 10.3389/fimmu.2017.01544.
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martínez-García, M., Rovira, A., Rojo, F., Albanell, J., & López-Botet, M. (2017). Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in immunology, 81544. https://doi.org/10.3389/fimmu.2017.01544
Muntasell, Aura, et al. "Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy." Frontiers in immunology vol. 8 (2017): 1544. doi: https://doi.org/10.3389/fimmu.2017.01544
Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. PMID: 29181007; PMCID: PMC5694168.
Copy Download .nbib Format: NLM
GABARAP-mediated targeting of PI4K2A/PI4KIIα to autophagosomes regulates PtdIns4P-dependent autophagosome-lysosome fusion.

Autophagy

Albanesi J, Wang H, Sun HQ, Levine B, Yin H.
PMID: 26391226
Autophagy. 2015 Nov 02;11(11):2127-2129. doi: 10.1080/15548627.2015.1093718.

For decades, phosphatidylinositol 4-phosphate (PtdIns4P) was considered primarily as a precursor in the synthesis of phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P

Cite
Albanesi J, Wang H, Sun HQ, et al. GABARAP-mediated targeting of PI4K2A/PI4KIIα to autophagosomes regulates PtdIns4P-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(11):2127-2129doi: 10.1080/15548627.2015.1093718.
Albanesi, J., Wang, H., Sun, H. Q., Levine, B., & Yin, H. (2015). GABARAP-mediated targeting of PI4K2A/PI4KIIα to autophagosomes regulates PtdIns4P-dependent autophagosome-lysosome fusion. Autophagy, 11(11), 2127-2129. https://doi.org/10.1080/15548627.2015.1093718
Albanesi, Joseph, et al. "GABARAP-mediated targeting of PI4K2A/PI4KIIα to autophagosomes regulates PtdIns4P-dependent autophagosome-lysosome fusion." Autophagy vol. 11,11 (2015): 2127-2129. doi: https://doi.org/10.1080/15548627.2015.1093718
Albanesi J, Wang H, Sun HQ, Levine B, Yin H. GABARAP-mediated targeting of PI4K2A/PI4KIIα to autophagosomes regulates PtdIns4P-dependent autophagosome-lysosome fusion. Autophagy. 2015 Nov 02;11(11):2127-2129. doi: 10.1080/15548627.2015.1093718. PMID: 26391226; PMCID: PMC4824573.
Copy Download .nbib Format: NLM
Trithia-cyanuric acid: a second triclinic polymorph.

Acta crystallographica. Section E, Structure reports online

Brito I, Albanez J, Bolte M.
PMID: 21588719
Acta Crystallogr Sect E Struct Rep Online. 2010 Aug 21;66:o2382-3. doi: 10.1107/S1600536810033234.

The title compound, C(3)H(3)N(3)S(3), is a triclinic modification. The other reported modification crystallizes with just one mol-ecule in the asymmetric unit, [Guo et al. (2006 ▶). Cryst. Growth Des.6, 846-848] and was solved by power X-ray diffraction data. The...

Cite
Brito I, Albanez J, Bolte M. Trithia-cyanuric acid: a second triclinic polymorph. Acta Crystallogr Sect E Struct Rep Online. 2010;66:o2382-3doi: 10.1107/S1600536810033234.
Brito, I., Albanez, J., & Bolte, M. (2010). Trithia-cyanuric acid: a second triclinic polymorph. Acta crystallographica. Section E, Structure reports online, 66o2382-3. https://doi.org/10.1107/S1600536810033234
Brito, Iván, et al. "Trithia-cyanuric acid: a second triclinic polymorph." Acta crystallographica. Section E, Structure reports online vol. 66 (2010): o2382-3. doi: https://doi.org/10.1107/S1600536810033234
Brito I, Albanez J, Bolte M. Trithia-cyanuric acid: a second triclinic polymorph. Acta Crystallogr Sect E Struct Rep Online. 2010 Aug 21;66:o2382-3. doi: 10.1107/S1600536810033234. PMID: 21588719; PMCID: PMC3007918.
Copy Download .nbib Format: NLM
Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer.

Translational oncology

Jiang Z, Albanese J, Kesterson J, Warrick J, Karabakhtsian R, Dadachova E, Phaëton R.
PMID: 31325765
Transl Oncol. 2019 Oct;12(10):1289-1295. doi: 10.1016/j.tranon.2019.06.003. Epub 2019 Jul 17.

Nearly all cases of cervical cancer are initiated by persistent infection with high-risk strains of human papillomavirus (hr-HPV). When hr-HPV integrates into the host genome, the constitutive expression of oncogenic HPV proteins E6 and E7 function to disrupt p53...

Cite
Jiang Z, Albanese J, Kesterson J, et al. Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer. Transl Oncol. 2019;12(10):1289-1295doi: 10.1016/j.tranon.2019.06.003.
Jiang, Z., Albanese, J., Kesterson, J., Warrick, J., Karabakhtsian, R., Dadachova, E., & Phaëton, R. (2019). Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer. Translational oncology, 12(10), 1289-1295. https://doi.org/10.1016/j.tranon.2019.06.003
Jiang, Zewei, et al. "Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer." Translational oncology vol. 12,10 (2019): 1289-1295. doi: https://doi.org/10.1016/j.tranon.2019.06.003
Jiang Z, Albanese J, Kesterson J, Warrick J, Karabakhtsian R, Dadachova E, Phaëton R. Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer. Transl Oncol. 2019 Oct;12(10):1289-1295. doi: 10.1016/j.tranon.2019.06.003. Epub 2019 Jul 17. PMID: 31325765; PMCID: PMC6642219.
Copy Download .nbib Format: NLM
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.

Oncoimmunology

Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E.
PMID: 31069160
Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019.

No abstract available.

Cite
Hardy-Werbin M, Rocha P, Arpi O, et al. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology. 2019;8(6):e1593810doi: 10.1080/2162402X.2019.1593810.
Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, �. �., Nonell, L., Durán, X., Villanueva, X., Joseph-Pietras, D., Nolan, L., Danson, S., Griffiths, R., Lopez-Botet, M., Rovira, A., Albanell, J., Ottensmeier, C., & Arriola, E. (2019). Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology, 8(6), e1593810. https://doi.org/10.1080/2162402X.2019.1593810
Hardy-Werbin, Max, et al. "Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer." Oncoimmunology vol. 8,6 (2019): e1593810. doi: https://doi.org/10.1080/2162402X.2019.1593810
Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019. PMID: 31069160; PMCID: PMC6492977.
Copy Download .nbib Format: NLM
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

European journal of cancer (Oxford, England : 1990)

Albanell J, Martínez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J, Virizuela JA, de la Haba-Rodríguez J, Sánchez-Rovira P, González-Cortijo L, Margelí M, Sánchez-Muñoz A, Antón A, Casas M, Bezares S, Rojo F.
PMID: 34902765
Eur J Cancer. 2021 Dec 10;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Epub 2021 Dec 10.

BACKGROUND: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remains uncharacterized.PATIENTS AND METHODS: In this randomized (1:1), double-blind, phase...

Cite
Albanell J, Martínez MT, Ramos M, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur J Cancer. 2021;161:26-37doi: 10.1016/j.ejca.2021.11.010.
Albanell, J., Martínez, M. T., Ramos, M., O'Connor, M., de la Cruz-Merino, L., Santaballa, A., Martínez-Jañez, N., Moreno, F., Fernández, I., Alarcón, J., Virizuela, J. A., de la Haba-Rodríguez, J., Sánchez-Rovira, P., González-Cortijo, L., Margelí, M., Sánchez-Muñoz, A., Antón, A., Casas, M., Bezares, S., & Rojo, F. (2021). Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). European journal of cancer (Oxford, England : 1990), 16126-37. https://doi.org/10.1016/j.ejca.2021.11.010
Albanell, J, et al. "Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER)." European journal of cancer (Oxford, England : 1990) vol. 161 (2021): 26-37. doi: https://doi.org/10.1016/j.ejca.2021.11.010
Albanell J, Martínez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J, Virizuela JA, de la Haba-Rodríguez J, Sánchez-Rovira P, González-Cortijo L, Margelí M, Sánchez-Muñoz A, Antón A, Casas M, Bezares S, Rojo F. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur J Cancer. 2021 Dec 10;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Epub 2021 Dec 10. PMID: 34902765.
Copy Download .nbib Format: NLM
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J.
PMID: 34385295
Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12.

PURPOSE: To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab.EXPERIMENTAL DESIGN: Characterization of NRG1 expression in tumor cell lines, in tumor specimens, and...

Cite
Guardia C, Bianchini G, Arpí-LLucià O, et al. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clin Cancer Res. 2021;27(18):5096-5108doi: 10.1158/1078-0432.CCR-20-2915.
Guardia, C., Bianchini, G., Arpí-LLucià, O., Menendez, S., Casadevall, D., Galbardi, B., Dugo, M., Servitja, S., Montero, J. C., Soria-Jiménez, L., Sabbaghi, M., Peña, R., Madoz-Gúrpide, J., Lloveras, B., Lluch, A., Eroles, P., Arribas, J., Pandiella, A., Gianni, L., Rojo, F., Rovira, A., & Albanell, J. (2021). Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(18), 5096-5108. https://doi.org/10.1158/1078-0432.CCR-20-2915
Guardia, Cristina, et al. "Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,18 (2021): 5096-5108. doi: https://doi.org/10.1158/1078-0432.CCR-20-2915
Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12. PMID: 34385295.
Copy Download .nbib Format: NLM
Dynamic Behavior of Vitronectin at the Cell-Material Interface.

ACS biomaterials science & engineering

Toromanov G, Gugutkov D, Gustavsson J, Planell J, Salmerón-Sánchez M, Altankov G.
PMID: 33429524
ACS Biomater Sci Eng. 2015 Oct 12;1(10):927-934. doi: 10.1021/acsbiomaterials.5b00147. Epub 2015 Sep 21.

Considering that vitronectin (VN) can promote both cell adhesion and matrix degradation, it is likely to play a dual role at the cell-biomaterial interface. In this paper we therefore describe details of the dynamic interplay between matrix adhesion and...

Cite
Toromanov G, Gugutkov D, Gustavsson J, et al. Dynamic Behavior of Vitronectin at the Cell-Material Interface. ACS Biomater Sci Eng. 2015;1(10):927-934doi: 10.1021/acsbiomaterials.5b00147.
Toromanov, G., Gugutkov, D., Gustavsson, J., Planell, J., Salmerón-Sánchez, M., & Altankov, G. (2015). Dynamic Behavior of Vitronectin at the Cell-Material Interface. ACS biomaterials science & engineering, 1(10), 927-934. https://doi.org/10.1021/acsbiomaterials.5b00147
Toromanov, Georgi, et al. "Dynamic Behavior of Vitronectin at the Cell-Material Interface." ACS biomaterials science & engineering vol. 1,10 (2015): 927-934. doi: https://doi.org/10.1021/acsbiomaterials.5b00147
Toromanov G, Gugutkov D, Gustavsson J, Planell J, Salmerón-Sánchez M, Altankov G. Dynamic Behavior of Vitronectin at the Cell-Material Interface. ACS Biomater Sci Eng. 2015 Oct 12;1(10):927-934. doi: 10.1021/acsbiomaterials.5b00147. Epub 2015 Sep 21. PMID: 33429524.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 82 entries